利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

44 条记录 (耗时 0.052 秒)

    Method for preventing and treating Alzheimer's disease
    4.
    发明授权
    Method for preventing and treating Alzheimer's disease 失效
    预防和治疗阿尔茨海默病的方法

    公开(公告)号：US08022180B2

    公开(公告)日：2011-09-20

    申请号：US11630679

    申请日：2005-07-06

    申请人： Frank Mattner ,  Walter Schmidt

    发明人： Frank Mattner ,  Walter Schmidt

    IPC分类号： A61K38/00 ,  A61K38/04 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00

    CPC分类号： G01N33/6896 ,  A61K39/0007 ,  G01N2800/2821

    摘要： The invention relates to the use of a compound comprising the following amino acid sequence X1X2X3X4X5X6X7, wherein X1 is an amino acid, except of C, X2 is an amino acid, except of C, X3 is an amino acid, except of C, X4 is an amino acid, except of C, X5 is an amino acid, except of C, X6 is not present or any amino acid, X7 is not present or any amino acid, and wherein X1X2X3X4X5X6 is not DAEFRH, said compound having a binding capacity to an antibody being specific for the natural N-terminal Aβ42 sequence DAEFRH, and 5-mers thereof having a binding capacity to said antibody being specific for the natural N-terminal Aβ42 sequence DAEFRH, for the preparation of a vaccine for Alzheimer's disease.

    摘要翻译： 本发明涉及以下氨基酸序列X1X2X3X4X5X6X7的化合物，其中X1为氨基酸，C除外，X2为氨基酸，C除外，X为氨基酸，C为X，X 4为 氨基酸除C以外，X5为氨基酸，C为X6，不存在X6，不存在任何氨基酸X7或氨基酸，X1X2X3X4X5X6不为DAEFRH，所述化合物的结合能力为 对于天然N-末端A末端A和Bgr 42序列DAEFRH具有特异性的抗体，其具有对所述抗体具有结合能力的5-序列，其对于天然N末端A和Bgr 42序列DAEFRH是特异性的，用于制备阿尔茨海默病 疾病。

    Methods for preventing and treating Alzheimer's disease
    5.
    发明授权
    Methods for preventing and treating Alzheimer's disease 有权
    预防和治疗阿尔茨海默病的方法

    公开(公告)号：US07732568B2

    公开(公告)日：2010-06-08

    申请号：US10540551

    申请日：2004-01-13

    申请人： Frank Mattner

    发明人： Frank Mattner

    IPC分类号： A61K38/00

    CPC分类号： C07K14/4711 ,  A61K38/08 ,  A61K38/10 ,  A61K38/1709 ,  C07K7/06

    摘要： The present invention relates to methods for preventing and treating Alzheimer's disease (AD). An Aβ42 mimotope is used for vaccination against AD. The mimotope induces the production of antibodies against Aβ42 but not against the native APP. The mimotope is functionally similar to, but not structurally identical with DAEFRH (SEQ ID NO: 1) which is a part of the naturally-occurring Aβ42 sequence.

    摘要翻译： 本发明涉及预防和治疗阿尔茨海默氏病（AD）的方法。 A＆bgr; 42模拟技术用于接种AD。 模拟表型诱导产生针对A＆bgr的抗体42，而不是针对天然APP。 模拟表达功能上与DAEFRH（SEQ ID NO：1）功能相似但并不完全相同，它是天然存在的A＆bgr 42序列的一部分。

    Vaccine Composition Comprising An Antigen And A Peptide Having Adjuvant Properties
    6.
    发明申请
    Vaccine Composition Comprising An Antigen And A Peptide Having Adjuvant Properties 有权
    包含抗原和具有佐剂性质的肽的疫苗组合物

    公开(公告)号：US20090123486A1

    公开(公告)日：2009-05-14

    申请号：US12124785

    申请日：2008-05-21

    申请人： Jorg Fritz ,  Frank Mattner ,  Wolfgang Zauner ,  Eszter Nagy ,  Michael Buschle

    发明人： Jorg Fritz ,  Frank Mattner ,  Wolfgang Zauner ,  Eszter Nagy ,  Michael Buschle

    IPC分类号： A61K39/00 ,  A61K39/39

    CPC分类号： C07K7/06 ,  A61K39/0011 ,  A61K39/39 ,  A61K2039/55516 ,  Y02A50/412

    摘要： The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R1-XZXZNXZX-R2, whereby N is a whole number between 3 and 7, preferably 5, X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and R1 and R2 are selected independently one from the other from the  group consisting of —H, —NH2, —COCH3, —COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide; X-R2 may also be an amide, ester or thioester of the C-terminal amino acid residue, as well as the use of said peptide for enhancing a patient's adaptive immune response to an antigen.

    摘要翻译： 本发明涉及包含至少一种抗原和包含序列R1-XZXZNXZX-R2的肽的疫苗，其中N为3至7之间的整数，优选5，X为带正电荷的天然和/或非天然 氨基酸残基，Z是选自L，V，I，F和/或W的氨基酸残基，R 1和R 2彼此独立地选自-H，-NH 2， -COCH 3，-COH，具有多达20个氨基酸残基的肽或肽反应性基团或具有或不具有肽的肽接头; X-R2也可以是C末端氨基酸残基的酰胺，酯或硫酯，以及所述肽用于增强患者对抗原的适应性免疫应答的用途。

    Method for Preventing and Treating Alzheimer's Disease
    7.
    发明申请
    Method for Preventing and Treating Alzheimer's Disease 失效
    预防和治疗阿尔茨海默病的方法

    公开(公告)号：US20090004210A1

    公开(公告)日：2009-01-01

    申请号：US11630679

    申请日：2005-07-06

    申请人： Frank Mattner ,  Walter Schmidt

    发明人： Frank Mattner ,  Walter Schmidt

    IPC分类号： A61K39/00 ,  C07K7/06 ,  C07K4/00 ,  A61K38/08 ,  C40B30/04

    CPC分类号： G01N33/6896 ,  A61K39/0007 ,  G01N2800/2821

    摘要： The invention relates to the use of a compound comprising the following amino acid sequence X1X2X3X4X5X6X7, wherein X1 is an amino acid, except of C, X2 is an amino acid, except of C, X3 is an amino acid, except of C, X4 is an amino acid, except of C, X5 is an amino acid, except of C, X6 is not present or any amino acid, X7 is not present or any amino acid, and wherein X1X2X3X4X5X6 is not DAEFRH, said compound having a binding capacity to an antibody being specific for the natural N-terminal Aβ42 sequence DAEFRH, and 5-mers thereof having a binding capacity to said antibody being specific for the natural N-terminal Aβ42 sequence DAEFRH, for the preparation of a vaccine for Alzheimer's disease.

    摘要翻译： 本发明涉及以下氨基酸序列X1X2X3X4X5X6X7的化合物，其中X1为氨基酸，C除外，X2为氨基酸，C除外，X为氨基酸，C为X，X 4为 氨基酸除C以外，X5为氨基酸，C为X6，不存在X6，不存在任何氨基酸X7或氨基酸，X1X2X3X4X5X6不为DAEFRH，所述化合物的结合能力为 针对天然N末端Abeta42序列DAEFRH特异的抗体及其对所述抗体的结合能力的5聚体对于天然N末端Aβ42序列DAEFRH是特异性的，用于制备阿尔茨海默氏病疫苗。

    Vaccine composition comprising an antigen and a peptide having adjuvant properties
    10.
    发明授权
    Vaccine composition comprising an antigen and a peptide having adjuvant properties 有权
    包含抗原和具有佐剂性质的肽的疫苗组合物

    公开(公告)号：US08361476B2

    公开(公告)日：2013-01-29

    申请号：US10399442

    申请日：2001-10-18

    申请人： Jörg Fritz ,  Frank Mattner ,  Wolfgang Zauner ,  Eszter Nagy ,  Michael Buschle

    发明人： Jörg Fritz ,  Frank Mattner ,  Wolfgang Zauner ,  Eszter Nagy ,  Michael Buschle

    IPC分类号： A61K39/00 ,  A61K45/00 ,  A61K47/30 ,  C07K1/00 ,  C07K2/00 ,  C07K9/00

    CPC分类号： C07K7/06 ,  A61K39/0011 ,  A61K39/39 ,  A61K2039/55516 ,  Y02A50/412

    摘要： The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R1—XZXZNXZX—R2, whereby N is a whole number between 3 and 7, preferably 5, X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and R1 and R2 are selected independantly one from the other from the group consisting of —H, —NH2, —COCH3, —COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide; X—R2 may also be an amide, ester or thioester of the C-terminal amino acid residue, as well as the use of said peptide for the preparation of an adjuvant for enhancing the immune response to at least one antigen.

    摘要翻译： 本发明涉及包含至少一种抗原和包含序列R1-XZXZNXZX-R2的肽的疫苗，其中N为3至7之间的整数，优选为5，X为带正电荷的天然和/或非天然 氨基酸残基，Z是选自L，V，I，F和/或W的氨基酸残基，R 1和R 2独立地选自-H，-NH 2， -COCH 3，-COH，具有多达20个氨基酸残基的肽或肽反应性基团或具有或不具有肽的肽接头; X-R2也可以是C末端氨基酸残基的酰胺，酯或硫酯，以及所述肽用于制备用于增强对至少一种抗原的免疫应答的佐剂的用途。